Verition Fund Management LLC
Institutional investor · Portfolio as of Q1 2020
Top Holdings561 positions
Allergan PLC | 1.4M | $245.6M | 9.7% | — | — | — | Decreased — |
MELLANOX TECHNOLOGIES LTD | 930,300 | $112.9M | 4.5% | — | — | — | Increased — |
| 88.5M | $98.2M | 3.9% | — | — | — | New 83 | |
MELLANOX TECHNOLOGIES LTD | 758,900 | $92.1M | 3.6% | — | — | — | Increased — |
BCE Inc | 2M | $81.7M | 3.2% | — | — | — | New — |
iShares Core U.S. Aggregate Bond ETF | 599,668 | $69.2M | 2.7% | $95.49 | 0.00% | 1 qtr | New 77 |
Bank of Montreal | 1M | $50.3M | 2.0% | — | — | — | New — |
AbbVie Inc | 644,400 | $49.1M | 1.9% | — | — | — | Increased — |
iShares Floating Rate Bond ETF | 992,925 | $48.4M | 1.9% | $39.14 | -0.15% | 2 qtrssince 2019-Q4 | Increased 74 |
Allergan PLC | 239,400 | $42.4M | 1.7% | — | — | — | Decreased — |
AbbVie Inc | 554,400 | $42.2M | 1.7% | — | — | — | Increased — |
HP Inc | 2.3M | $40.3M | 1.6% | — | — | — | Increased — |
| 13.3M | $36.2M | 1.4% | — | — | 6 qtrssince 2018-Q4 | Unchanged 0 | |
| 23M | $35.3M | 1.4% | — | — | 6 qtrssince 2018-Q4 | Increased 49 | |
Tiffany & Co | 272,900 | $35.3M | 1.4% | — | — | — | Increased — |
Centene Corp | 561,400 | $33.4M | 1.3% | — | — | — | Increased — |
ROYAL DUTCH SHELL PLC SPON ADR B | 971,061 | $31.7M | 1.3% | $27.81 | 0.00% | 1 qtr | New 66 |
Tiffany & Co | 229,100 | $29.7M | 1.2% | — | — | — | Decreased — |
Enbridge Inc | 1M | $29.1M | 1.1% | — | — | — | New — |
HSBC Holdings PLC | 1M | $28.5M | 1.1% | $26.05 | -17.92% | 5 qtrssince 2019-Q1 | Increased 55 |
Verition Fund Management LLC manages $2.5B across 561 positions as of Q1 2020. Top holdings: AGN puts (9.7%), MLNX puts (4.5%), PRICELINE GRP INC (3.9%). Fund DNA: Diversified Scout. HoldingsIntel Score: 1.5/5.0.
Active quarter - 187 new positions, 616 exits, 121 increased. Top move: AGG (NEW, conviction 77). Portfolio: $2.5B across 561 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR